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LETTER TO THE EDITOR
The significance of early warning in chronic myeloid leukemia
Mario Tiribelli a, Gianni Binottob and Massimiliano Bonifacio c
aDivision of Hematology and BMT, Department of Experimental and Clinical Medical Sciences, Azienda Sanitaria Universitaria Integrata, Udine,
Italy; bDepartment of Medicine, Hematology and Clinical Immunology, Padua School of Medicine, Padua, Italy; cDepartment of Medicine, Section of
Hematology, University of Verona, Verona, Italy
Dear Editor:
We have read with great interest the manuscript by Eskazan
and colleagues entitled ‘Critical appraisal of European
LeukemiaNet (ELN) 2013 recommendations for the manage-
ment of chronic myeloid leukemia: is it early for a warning?’
[1]. After a revision of the relatively limited literature, the
authors conclude that there are still no solid data to suggest
a switch of therapy in patients with warning signs and that
long-term survival remains a highly significant endpoint in
CML patients. While we generally agree with these thoughts,
we would like to stress a couple of additional points on the
issue of ELN 2013 – defined ‘warning’.
The ELN recommendations defines warning as less than
partial cytogenetic response (PCyR) and/or BCR-ABL1 > 10%
(according to the International Scale – IS) at 3 months, less
than complete cytogenetic response (CCyR) and/or BCR-ABL
1 > 1%IS at 6 months, and BCR-ABL1 > 0.1% IS, i.e. no major
molecular response (MMR), at 12 months [2]. So, at the first
two time-points, conventionally considered as ‘early’ [3], both
cytogenetic and molecular status define response, while at
12 months only BCR-ABL1 level > 0.1 to 1%IS identifies warn-
ing patients, as anything less than CCyR is regarded as a
failure. Our group analyzed the outcome of 216 CML patients
treated with front-line standard dose (400 mg/day) imatinib
with discordant cytogenetic and molecular responses at 3 and
6 months [4]. Patients with even a single warning sign at
3 months (i.e. no PCyR or BCR-ABL1 > 10%IS) had a signifi-
cantly lower chance to obtain a subsequent CCyR (37% com-
pared to 85% in patients with concordant optimal cytogenetic
and molecular responses) and worse failure-free survival (FFS)
(39% vs. 81% at 48 months). Similarly, a warning sign at
6 months identified patients less prone to attain a MMR at
12 months (17% vs. 82% in concordantly optimal patients) and
with worse FFS (62% vs. 88%) [4].
In our experience, most discordant patients had a ‘molecular
warning’, as 15/17 discordant at 3 months were in PCyR or better
but with BCR-ABL1 transcript > 10%IS and at 6 months 20/25
discordant were in CCyR with BCR-ABL1 > 1%IS. This finding is an
indirect confirmation of the importance of a BCR-ABL1 transcript
level < 10%IS at 3 months (now defined ‘early molecular response’
[EMR]) as a positive predictor of long-term outcome, as reported
by different studies [5,6]. Despite EMR is gaining ground as a factor
for an early switch of therapy, as suggested by NCCN guidelines
[7], some reports indicate, in line with ELN recommendations, to
consider also the 6-month cytogenetic or molecular status to
assess a two-point evaluation of response to tyrosine kinase inhi-
bitor (TKI) therapy. The MDACC group analyzed the outcome of
453 CML patients treated with different TKIs, finding that 19 out of
44 patients (43%) not achieving major (i.e. optimal) cytogenetic
response (MCyR) at 3 months obtained this response at 6 months
and had an outcome comparable to patients achieving an earlier
MCyR [8]. A Canadian study reviewed 320 patients receiving
imatinib therapy with 3- and 6-month BCR-ABL1 transcript levels
available, reporting that patients not achieving an EMR at
3 months but with BCR-ABL1 transcript < 1% at 6 months
(n = 18) had similar FFS, progression-free survival (PFS), and overall
survival (OS) compared to patients in EMR (n = 184) [9]. Taken
together, these data suggest that cytogenetic and molecular
response at 6 months can identify a subgroup with favorable
outcome among patients ‘warning’ at 3 months. However, con-
sidering patients with cytogenetic and/or molecular warning at
3 months in our series (n = 41), only 2 had a subsequent optimal
cytogenetic and molecular response at 6 months (unpublished).
Moreover, we found that the rates of warning responses at 3 and
6months were higher in cases with b2a2 BCR-ABL1 transcript type
compared to those with b3a2 variant (32% vs. 24% at 3 months
and 31% vs. 12% at 6 months, respectively) [10].
If there is still debate on the practical significance of a warning
at 3 or 6 months, even less consensus and significantly less data
are about the meaning of a late (i.e. at 12 months) warning.
Starting from their database of 483 patients treated with four
different TKI strategies, colleagues at MDACC found no benefit,
in term of survival, in patients achieving MMR while in CCyR, even
if their landmark analysis was performed at 18 and 24months, and
not at the 12-month time-point [11]. A landmark analysis of PFS
and OS on the bases of molecular response at 12 months of
imatinib performed in 128 patients from our database did not
find any difference between patients inMMRor not (unpublished).
Concordantly, a Spanish group showed that, in 198 patients trea-
ted with standard-dose imatinib and in CCyR without MMR at
12 months, a switch to a second-generation TKI was associated
with a higher probability of subsequently major and deep mole-
cular response, but no advantage in terms of PFS and OS and
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higher rates of discontinuation for adverse events, compared to
patients continuing imatinib [12].
Hopefully, more information on the therapeutic approach to
‘warning’ patients will come from an upcoming study of the
GIMEMA Working Party on CML study aimed to evaluate efficacy
of nilotinib frontline versus imatinib followed by switch to nilotinib
in the case of absence of ELN-defined optimal response at 3, 6, or
12 months [13].
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